News
- ETX-636 advanced to the clinic following preclinical observations showcasing superior potency and selectivity for all mutant forms of PI3Kα while sparing wildtype PI3Kα Ensem Therapeutics, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback